Asymchem Laboratories (Tianjin) Co (ASLTY) Fair Value & Analysis
Healthcare · US · Market cap $4.6B
Fair value as of: Jun 24, 2026
Analysis
Asymchem Laboratories (Tianjin) Co (ASLTY) currently trades at $6.37, while our model-based Fair Value estimate is $3.72 — implying the stock looks roughly 41.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities. The company was founded in 1998 and is headquartered in Tianjin, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Asymchem Laboratories (Tianjin) Co (ASLTY) undervalued?
What is the fair value of ASLTY?
What is the quality score of ASLTY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.